Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology

• Published in: Japanese journal of antibiotics Vol. 39; no. 6; p. 1612
• Main Authors: Hatase, T, Kawano, K, Fukagawa, R, Hirai, H, Ohokura, N, Akagi, T, Tsunawaki, A, Kato, T
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-06-1986
• Subjects: Adult; Aged; Aged, 80 and over; Amniotic Fluid - metabolism; Bacterial Infections - drug therapy; Child; Cilastatin; Cyclopropanes - blood; Cyclopropanes - metabolism; Cyclopropanes - therapeutic use; Dipeptidases - antagonists & inhibitors; Drug Combinations; Female; Fetal Blood - metabolism; Genital Diseases, Female - drug therapy; Genitalia, Female - metabolism; Humans; Imipenem; Maternal-Fetal Exchange; Middle Aged; Pregnancy; Thienamycins - blood; Thienamycins - metabolism; Thienamycins - therapeutic use
• ISSN: 0368-2781
• DOI: 10.11553/antibiotics1968b.39.1612

Fundamental and clinical studies on imipenem/cilastatin sodium (MK-0787/MK-0791) were carried out and the results obtained were summarized below. The transfer of MK-0787/MK-0791 into female genital organ tissues was found to be satisfactory. The transfer of MK-0787/MK-0791 into umbilical arterial blood, umbilical venous blood and amniotic fluid was relatively good. A dose of 1,000 mg/1,000 mg per day of MK-0787/MK-0791 was given to each of 6 gynecology patients for 5-22 days and satisfactory clinical effect was obtained in 5 patients out of 6 patients. No notable side effects or abnormal laboratory findings were observed except for a moderate in elevation in S-GOT/S-GPT in 1 case.